From GlobeNewswire: 2025-05-26 09:35:00

The global Artificial Heart Market was valued at USD 2.87 billion in 2023, expected to reach USD 7.55 billion by 2032 with a CAGR of 11.36%. Demand is driven by an aging population, increased cardiovascular disorders, and technological advancements in mechanical circulatory support systems.

The U.S. Artificial Heart Market was worth USD 1.43 billion in 2023, projected to grow to USD 3.46 billion by 2032 at a CAGR of 10.34%. Long-term cardiac support devices are crucial due to rising heart failure cases and limited donor organs, offering hope to patients needing transplants.

With over 6.5 million Americans affected by chronic heart diseases, the demand for advanced cardiac assist solutions is rising. Agencies like the U.S. FDA and NIH are supporting innovation in artificial heart devices to address the increasing prevalence of heart failure worldwide.

The global prevalence of heart failure, affecting over 26 million people, is fueling the need for artificial hearts. Lifestyle factors like obesity and diabetes contribute to the rise in end-stage cardiac disorders, creating a demand for advanced cardiac devices like LVADs and TAHs.

The older population is expanding rapidly, increasing the demand for cardiac assist devices. The UN predicts a quadruple increase in the population aged 65 and above by 2025, driving market acceptance with advancements in device insertion techniques and patient outcomes.

LVADs lead the Artificial Heart Market with 76.2% share, providing long-term cardiac support for patients with heart failure. Destination therapy emerges as a top revenue generator, offering a permanent treatment option for patients ineligible for transplants, with advancements in telemonitoring and wearable technology enhancing patient confidence.

The North America region dominates the global Artificial Heart Market in 2023, supported by robust healthcare infrastructure and government funding for cardiovascular innovation. LVADs, heart-lung machines, and total artificial hearts are key segments driving market growth. The European region is a hub for artificial heart makers like SynCardia Systems and Abbott, supported by government-funded healthcare systems and growing clinical studies. The Asia Pacific region is expected to see rapid growth due to increased healthcare investments and better availability to surgical procedures. Abbott Laboratories received FDA clearance for pediatric use of the HeartMate 3 LVAD, with the National Institutes of Health granting a $25 million grant for bioengineered heart pump research. The Cardiac Assist Devices Market is projected to reach $2.24 billion by 2032, with the Ventricular Assist Device Market expected to reach $3.3 billion by the same year. The Cardiovascular Devices Market is projected to grow at a 7.2% CAGR during the forecast period of 2024-2032, while the Wearable Cardiac Devices Market size is projected to reach $25.71 billion by 2032. SNS Insider provides market research and consulting services globally, offering clients the knowledge and data needed to make informed decisions in a changing market landscape.



Read more at GlobeNewswire: Artificial Heart Market to Reach USD 7.55 Billion by 2032,